BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry.

Trial Profile

BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Cangrelor (Primary)
  • Indications Coronary thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIDGE
  • Sponsors The Medicines Company
  • Most Recent Events

    • 14 Nov 2014 The Medicines Company plans to resubmit an NDA for cangrelor by the end of 2014 with respect to the PCI indication, according to a media release.
    • 14 Nov 2014 The NDA filing was based on data from the CHAMPION PHOENIX, CHAMPION PLATFORM, CHAMPION PCI, and BRIDGE, according to a media release from the The Medicines Company.
    • 18 Jan 2012 Primary endpoint 'Platelet-aggregation' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top